CN111447931B - 抗癌/抗纤维化化合物 - Google Patents

抗癌/抗纤维化化合物 Download PDF

Info

Publication number
CN111447931B
CN111447931B CN201880049675.1A CN201880049675A CN111447931B CN 111447931 B CN111447931 B CN 111447931B CN 201880049675 A CN201880049675 A CN 201880049675A CN 111447931 B CN111447931 B CN 111447931B
Authority
CN
China
Prior art keywords
compound
salt
isoquinoline
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880049675.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN111447931A (zh
Inventor
戴维·M·雅布隆斯
许维
尤亮
刘舒
袁沈东
马成勋
莫里森·马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metkin Treatment Co
University of California San Diego UCSD
Original Assignee
Metkin Treatment Co
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metkin Treatment Co, University of California San Diego UCSD filed Critical Metkin Treatment Co
Publication of CN111447931A publication Critical patent/CN111447931A/zh
Application granted granted Critical
Publication of CN111447931B publication Critical patent/CN111447931B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880049675.1A 2017-07-31 2018-07-31 抗癌/抗纤维化化合物 Active CN111447931B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539237P 2017-07-31 2017-07-31
US62/539,237 2017-07-31
PCT/US2018/044663 WO2019028059A1 (en) 2017-07-31 2018-07-31 ANTICANCER COMPOUNDS / ANTI-FIBROSIS

Publications (2)

Publication Number Publication Date
CN111447931A CN111447931A (zh) 2020-07-24
CN111447931B true CN111447931B (zh) 2024-01-26

Family

ID=65233035

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049675.1A Active CN111447931B (zh) 2017-07-31 2018-07-31 抗癌/抗纤维化化合物

Country Status (6)

Country Link
US (1) US11932606B2 (enExample)
EP (1) EP3661512A4 (enExample)
JP (1) JP7277390B2 (enExample)
CN (1) CN111447931B (enExample)
CA (1) CA3067871A1 (enExample)
WO (1) WO2019028059A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028059A1 (en) * 2017-07-31 2019-02-07 The Regents Of The University Of California ANTICANCER COMPOUNDS / ANTI-FIBROSIS
EP4003339A4 (en) * 2019-07-30 2023-02-22 Sanford Burnham Prebys Medical Discovery Institute DOPAMINE RECEPTOR D1 AGONISTS AND METHODS OF USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481289A (zh) * 2009-04-17 2012-05-30 赛林药物股份有限公司 治疗与蛋白激酶ck2活性有关的疾病的方法
CN102647904A (zh) * 2009-09-16 2012-08-22 赛林药物股份有限公司 新型三环蛋白激酶调节剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648021A (en) * 1994-01-17 1997-07-15 Hoechst Aktiengesellschaft Phenanthrene derivatives and their use in liquid-crystalline mixtures
DE19524230A1 (de) * 1995-07-04 1997-01-09 Hoechst Ag Fluorierte Phenanthren-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
KR19990029052A (ko) * 1995-07-17 1999-04-15 악커만 요아힘, 되르 클라우스 강유전성 액정 혼합물
EP1904449A4 (en) * 2005-07-08 2010-07-28 Merck Sharp & Dohme CHECKPOINT KINASE INHIBITORS
ES2528316T3 (es) * 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
US7910600B2 (en) * 2007-08-31 2011-03-22 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
US10432142B2 (en) * 2017-07-21 2019-10-01 Oracle International Corporation Voltage controlled oscillator with tunable inductor and capacitor
WO2019028059A1 (en) * 2017-07-31 2019-02-07 The Regents Of The University Of California ANTICANCER COMPOUNDS / ANTI-FIBROSIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481289A (zh) * 2009-04-17 2012-05-30 赛林药物股份有限公司 治疗与蛋白激酶ck2活性有关的疾病的方法
CN102647904A (zh) * 2009-09-16 2012-08-22 赛林药物股份有限公司 新型三环蛋白激酶调节剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CID 160447;PUBCHEM;《https://pubchem.ncbi.nlm.nih.gov/compound/160447》;20050327;1-16 *
CID 69571661;PUBCHEM;《https://pubchem.ncbi.nlm.nih.gov/compound/69571661》;20121201;1-8 *

Also Published As

Publication number Publication date
EP3661512A1 (en) 2020-06-10
JP2020529396A (ja) 2020-10-08
WO2019028059A1 (en) 2019-02-07
US20230192621A1 (en) 2023-06-22
JP7277390B2 (ja) 2023-05-18
CN111447931A (zh) 2020-07-24
US11932606B2 (en) 2024-03-19
EP3661512A4 (en) 2020-12-30
CA3067871A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
CN115843272B (zh) Nek7激酶的抑制剂
CN108383836B (zh) 作为mek抑制剂的杂环基化合物
JP2024514844A (ja) Ｍｙｔ１阻害剤を含む併用治療
CN110092745B (zh) 一种含芳环的化合物及其应用
TW201726695A (zh) （ｒ）-及（ｓ）-１-（３-（３-ｎ，ｎ-二甲基胺基羰基）苯氧基-４-硝苯基）-１-乙基-ｎ，ｎ’-雙（伸乙基）胺基磷酸酯、組合物及其使用及製備方法
BRPI0714880A2 (pt) inibidores da transcriptase reversa do hiv
CN106488910A (zh) Kras g12c的抑制剂
CN103068384A (zh) 表现出抗癌和抗增生活性的环丙基二甲酰胺以及类似物
US9809568B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2022517977A (ja) ネクローシス阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
CN109906224A (zh) 三唑吡啶化合物及其应用
EP4667468A1 (en) Compound for inhibiting nlrp3, preparation method, and use
CN109651359B (zh) 取代的烟酰胺类化合物及药物组合物及其用途
CN104177363A (zh) 双环杂环胺类Hedgehog信号通路抑制剂
JP2022500471A (ja) キヌクリジン−３−オン化合物および癌治療へのその使用
CN115745979A (zh) 一种蛋白靶向降解化合物及其用途
CA3241173A1 (en) Aromatic heterocyclic compounds, preparation method therefor and uses thereof
CN116075513A (zh) Nek7激酶的抑制剂
JP2025081626A (ja) ペンタミジンの類似体及びその使用
CN109476600B (zh) 吡啶硫酮、其药物组合物及其用于治疗增殖性、炎症性、神经变性或免疫-介导的疾病的治疗用途
CN111447931B (zh) 抗癌/抗纤维化化合物
CN117529321A (zh) Erk抑制剂和kras抑制剂的组合及其用途
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
US12357634B2 (en) 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy
CA2912627A1 (en) Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant